[ACN Newswire] – By Jake KingTwo pertinent announcements from Lexicon Pharmaceuticals (NASDAQ:LXRX) are giving shares a 7% lift on Friday morning. The company reported top-line data from the latest Phase II trial of telotristat … moreView todays social media effects on BMYView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – In an exclusive PropThink interview with ARIAD Pharmaceuticals (NASDAQ:ARIA), CEO Harvey J. Berger discusses the company’s lead product, ponatinib, a potential treatment for intolerant Chronic Myeloid … moreView todays social media effects on BMYView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – With Orphan Drug status and a largely-unmet medical need for its primary indication, ADVENTRX Pharmaceuticals (AMEX:ANX) expects its lead candidate, ANX-188, to be the company’s most important asset in … moreView todays social media effects on BMYView the latest stocks trending across Twitter. Click to view dashboard […]
